FASENRA EGPA US FDA APPROVAL
18 September 2024
Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial which showed…
77,250€
-0,32%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease
The FDA okays AstraZenecas Fasenra for treating adults with eosinophilic granulomatosis with polyangiitis. This is the second approved indication for…
AstraZeneca PLC (AZN) Meet the Management at ESMO 2024 Conference (Transcript)
…
Drugmakers bet billions that targeted radiation could become the next cancer breakthrough
Bristol Myers Squibb, AstraZeneca, Eli Lilly and other drug companies have invested some $10 billion on promising cancer technology behind…
Astrazeneca Aktie: Enttäuschende Studienergebnisse belasten Kurs
Die Astrazeneca-Aktie gerät unter Druck, nachdem die Deutsche Bank Research ihre Einschätzung von "Halten" auf "Verkaufen" herabgestuft und das Kursziel…